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A B S T R A C T
Picornaviruses (family Picornaviridae) are small, nonenveloped, positive-sense, single-stranded RNA viruses.
The members of this family are currently classified into 47 genera and 110 species. Of picornaviruses, entero-
and parechoviruses are associated with aseptic meningitis. They are transmitted via fecal-oral and respiratory
routes, and occasionally, these viruses may cause a brief viremia and gain access to central nervous system
(CNS). During the diagnostic screening of entero- and parechovirus types in Finland in year 2013−14, we
detected a cluster of echovirus 4 (E4) infections in young adults and adolescents. As E4 is infrequently detected
in Finland, we contacted several Northern and Central European laboratories that conduct routine surveillance
for enteroviruses and, for those who have had E4 cases, we send a query for E4 sequences and data. Here we
report CNS infections caused by E4 in Finland, Sweden, Norway, Denmark, Iceland and Germany in 2013 and
2014, and show that the E4 detected in these countries form a single lineage. In contrast, E4 strains circulating in
these countries preceding the year 2013, and those circulating elsewhere in Europe during 2013–2014, formed
several independent clusters.
1. Introduction
Picornaviruses (family Picornaviridae) are small, non-enveloped,
plus-sense, single-stranded RNA viruses. The members in this family are
currently classified into 40 genera and 94 species (www.picornaviridae.
com) and include several notorious pathogens including entero- and
parechoviruses, which are the most common causes of viral (aseptic)
meningitis [1,2]. Both entero- and parechoviruses are transmitted via
fecal-oral and respiratory routes. Occasionally, these viruses cause a
brief viremia and gain access to CNS. In particular, several enterovirus
(genus Enterovirus; EV) types including many echoviruses (e.g. E9, E11
E30) and numbered enteroviruses (e.g. EV-A71) and human par-
echovirus (genus Parechovirus) types 3 and 4 (PeV-A3, PeV-A4) have
been associated with central nervous system (CNS) infections causing
clinical conditions such as meningitis, encephalitis and acute flaccid
paralysis (AFP) [3–6,40,41]. Entero- and parechovirus infections are
common in infants (up to 2-years of age) and enterovirus infections in
older children and adolescents. In temperate zones, the infections have
seasonal pattern with incidence peak from late summer to late autumn.
Typically, several different enterovirus types circulate during each year
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[3,6,7].
During a routine surveillance, we detected a cluster of echovirus 4
(E4) infections in Finland, especially in adolescents (up to 15-years of
age) and adults (up to 31-years of age) with reported central nervous
system infection. Since E4 is infrequently detected in Finland [8], and
to gain more detailed insight into the molecular epidemiology of E4, a
query regarding E4 prevalence was sent to several Northern and Central
European laboratories that conduct routine surveillance for en-
teroviruses. Here we report the clinical aspects of E4 neurological in-
fection identified in Finland and the molecular-characteristics of E4
circulated in Finland, Sweden, Norway, Denmark, Iceland and Ger-
many. In contrast, E4 strains circulating in these countries preceding
the year 2013, and those circulating elsewhere in Europe formed sev-
eral independent clusters. In addition to E4 findings, other EV and PeV-
A cases during 2013–2014 in Finland are reported in this study.
2. Materials and methods
2.1. Sample collection in Finland
Altogether, 594 and 678 routine EV/PeV-A diagnostic samples
collected in 2013 and 2014, respectively, in Helsinki/Uusimaa hospital
district located in the Southern Finland, were included in the study. The
samples comprised cerebrospinal fluid (CSF), serum, feces, skin lesion/
vesicle and throat swabs sent for EV/PeV nucleic acid detection test
(NAT, described below) or for virus isolation (VC; described in [5]) at
Helsinki University Hospital (HUSLAB), Finland. From individuals,
different samples types with different combinations were sampled
during the year.
2.2. Virus isolation in cell cultures
Cell lines of Vero, GMK and A549 were routinely used for all sam-
ples types. The culture media consisted of 2% fetal bovine serum (FBS)
and antibiotics (penicillin streptomycin) and nystatin, and cell bottles
were incubated at 37 °C, and microscoped daily-base for cytopathic
effect (CPE).
2.3. RT-qPCR and genotyping assays
RNA was extracted from biological samples and cell-cultured posi-
tive supernatant using either QIAamp Viral RNA kit (Qiaqen Inc.,
Valencia, CA, USA) or EasyMag (bioMerieux) according to the manu-
facturer’s instructions. The extracted RNA was either processed im-
mediately or frozen at −70 °C and stored for further analysis.
The samples were tested for EV, PeV-A and human rhinovirus nu-
cleic acids by an in-house real time multiplex RT-qPCR for EV and PeV-
A, a real time RT-qPCR for human rhinoviruses, and a commercial rapid
molecular Xpert® EV test (Cepheid) for CSF samples. The validated in-
house real time multiplex RT-qPCR for EV and PeV-A was carried out
using the primers of Par30 (400 nM, 5′-GGTACCTTCTGGGCATCC
TTC-3′; [9]) and Par31 (400 nM, 5′-CTGGGGCCAAAAGCCA-3′ [10]),
PeV-A-probe (200 nM, 6ʹFAM-5′-AAACACTAGTTGTAHGGCCC-3′-MGB
[11]), EV-primers (400nnM, 5′-ACATGGTGTGAAGAGTCTATTGA
GCT-3′; 400 nM, 5′-CCAAAGTAGTCGGTTCCGC-3′) and probe (50 nM,
VIC-5′-TCCGGCCCCTGAATGCGGCTAAT- 3′-MGB) described by
Dierssen et al. [12], and Superscript® III Platinum® One-step qRT-PCR
System (Invitrogen, Carlsbad, CA, USA).
The validated real time RT-qPCR for human rhinoviruses was car-
ried out using in-house primers (500 nM, 5′- AAGGTGTGAAGAGCCCC
GTGT- 3′; 750 nM, 5′-GAAACACGGACACCCAAAGTAGT- 3′) and probe
(250 nM, 6ʹFAM - 5′-CCGGCCCCTGAATGYGGCTAACCT-3′-MGB) in
addition to Superscript® III Platinum® One-step qRT-PCR System
(Invitrogen, Carlsbad, CA, USA). Both multiplex-EV-PEV-A and human
rhinovirus real time RT-qPCRs were carried out using the PCR condi-
tions of 15min at 50 °C, 2min at 95 °C, followed by 45 cycles of 15 s at
95 °C and 50 s at 60 °C. The Xpert® EV test (Cepheid) was carried out
according to manufacturer´s instructions.
In order to type the virus strains, samples that were EV or PeV-A
RNA positive, or showed picornavirus-like cytopathic effect (CPE) in
virus cultivation, were subjected to conventional RT-PCRs targeting the
VP1 coding region (Leitch et al. 2011). For EV and PeV-A, method and
primers (each in final concentration of 500 nM) modified from Leitch
et al. [13] with One-step RT-PCR kit (Invitrogen) for the first round RT-
PCR and Phusion Flash (Thermo Scientific) for the second round PCR,
and primers (each in final concentration of 500 nM) and PeV-RT-PCR
method described in Kolehmainen et al. [11], were used, respectively.
Rhinovirus positive samples were not typed. The PCR products (ap-
prox.700−900bp) were sequenced at DNA sequencing and Genomic
service (Helsinki University, Institute of Biotechnology, Viikki, Hel-
sinki). Feces, CSF, and lesion/vesicle swabs sent for virus isolation using
A549, GMK and Vero cells and CPE positives were screened with real
time multiplex RT-qPCR for EV and PeV-A, and further VP1-typed,
accordingly, using the methods described above.
2.4. Sequence data collection
A query to obtain VP1 sequences from E4 samples detected, either
during 2013−14 or prior to that, was sent to a few European labora-
tories that conduct routine surveillance for enteroviruses. Altogether
seven laboratories, including The Public Health Agency of Sweden,
Norwegian Institute of Public Health (Norway), Statens Serum Institut
in Denmark, National University Hospital in Iceland, National
Reference Lab for Poliomyelitis and Enteroviruses in Germany, M.P.
Chumakov Institute of Poliomyelitis & Viral Encephalitides in Russia
and University Hospital of Lyon, France, reported E-4 infections,
whereas Österreichische Agentur für Gesundheit und
Ernährungssicherheit in Austria and University of Edinburgh in UK
Scotland had no confirmed E4 cases.
In addition to strains sequenced in this study, all available E4 VP1
sequences were downloaded from the GenBank. The sequences were
aligned using ClustalW algorithm implemented in MEGA7 software
[14]. The best fit substitution model was estimated using jModeltest
2.1.10 [15]. Phylogenetic tree was constructed using Bayesian Monte
Carlo Markov Chain (MCMC) method implemented in BEAST version
1.10 [16] using two different clock models (strict clock and log normal
relaxed clock) and three demographic models (constant, Bayesian
skyline and exponential models) [17,18]. The marginal likelihoods of
different model combinations were estimated using path sampling and
stepping stone methods [19] and Bayes factors (BF) were calculated for
each pair of models. The final analysis was conducted using K2+G
model of substitution, lognormal relaxed clock and Bayesian skyline
demographic model, which showed logBF> 80 to the other model
combinations in both stepping stone and path sampling analyses.
3. Results
In Finland, altogether 30 routine diagnostic samples (30/594 sam-
ples, 5.1 %; 19 NAT and 11 VC; three individuals had both NAT and VC
positive) from 27 patients in 2013, and 46 samples (46/678 samples,
6.8 %; 40 NAT and 6 VC; one individual had both NAT and VC positive)
from 45 patients in 2014, were positive for picornaviruses.
Sequencing was conducted for 45 samples acquired from 41 in-
dividuals (median age 6, range 0−59-years; 21 males, 20 females; year
2013, 15 individuals, year 2014, 26 individuals; Table 1) out of the 72
individuals (year 2013, 27 individuals; year 2014, 45 individuals), in
total. Most common sample types were CSF (N=15; 15/45 33 %),
vesicle (N= 12; 12/45, 27 %) and feces (N=11; 11/45, 24 %), fol-
lowed by serum (N=4; 4/45, 9%) and throat swab (N=3; 3/45, 7%).
Samples originated mostly from hospital district of Helsinki and Uu-
simaa.
Coxsackievirus A6 (CVA6) was the most common finding [N=12;
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12/41, 29 %), followed by echovirus 4 (E4, N=8; 8/41, 20 %), CVA16
(N=4; 4/41, 10 %), CVB4 (N=4; 10 %), E30 (N=3; 3/41, 7%),
CVB1 (N=2; 2/41, 5%) and CVB2 (N=2; 5%) (Table 1). In addition,
CVA2, CVA4, E2, E9 and E25 (N=1; 1/41, 2%) were detected during
the study period. CVA2, CVA6 and CVA16 were detected most com-
monly from vesicular lesion, whereas the most common sample type for
E2, E4, E9, E11, E30, CVB1 and CVB4 was CSF (Table 1). In addition,
two PeV-A3 isolates were detected from a serum sample originated
from North Savo, and a fecal sample from Helsinki and Uusimaa region
(Table 2). Both patients were neonates under two months old. Clinical
findings of E4 and other EVs and PeV-A3 cases in hospital district of
Helsinki and Uusimaa (HUS, Finland) were collected retrospectively
and are summarized in Table 2. From other hospital districts in Finland,
the data were not available (Table 2).
There were some differences in the number of circulating EV types
between 2013 and 2014. More EV cases were detected in 2014 than
during the year of 2013, however, the numbers are too low to conclude
reliable statistical difference. In 2014, there was more of E4 and CVA6
infections. Since 2008, CVA6 has been detected annually as the cau-
sative agent of hand, foot and mouth disease in Finland [7,39]. Inter-
estingly, the number of E4 detections among patients with suspected
CNS infection increased during the year 2014. In total two males and
five females (median age 24, range 14–31; median of 4 days in hospital,
range 0–5) were diagnosed for E4 infection. The C-reactive protein le-
vels were elevated in 6 out of seven E4 infected patients.
Since E4 is infrequently detected in Finland [8], a query for E4 se-
quences was sent and altogether five countries reported similar cases in
2013–2014 (Table 3); four cases were reported from Sweden, one from
Norway, five from Denmark, two from Iceland and ten from Germany.
In addition, 11 cases of E4 infections were reported from Germany
during years 2006–2012 (Table 3). Fourteen cases were reported from
Lyon, France between years 2008–2015, but none of these had occurred
during 2013–2014 (Table 3). Three cases were reported from Russia
during years 2003–2006, and one case from Denmark in 2010
(Table 3). In addition, six older E4 strains (years 1991–2008) from
Finland were included in the analysis. The country, median age, sample
types, year, age and sex of patients, and diagnosis/symptoms (when
available) are listed in Table 3.
The phylogenetic analysis suggested three highly divergent major
groups for E4 (Fig. 1). Of these, one contained a sole prototype strain
Pesacek isolated in Connecticut, USA in the year 1951, which showed
16.2–23.2 % divergence at nucleotide level (3.2–10.9 % at amino acid
Table 1
Forty-one entero- and parechovirus findings, which were sequenced during the years 2013-2014 in Helsinki University Hospital Laboratory (HUSLAB, Helsinki,
Finland).
Patient Age (y/m) Gender (f/m) Hospital District Sample type Sampling time (year/month) Sequenced virus type
1−13 5y f Southwest Finland throat swab 2013/07 CVA4
2−13 48y f North Savo CSF 2013/07 E2
3−13 1m f Helsinki and Uusimaa CSF 2013/08 E11
feces 2013/08 E11
4−13 23y f Helsinki and Uusimaa CSF 2013/09 E30
feces 2013/09 E30
5−13 1m f Helsinki and Uusimaa CSF 2013/09 CVB4
6−13 14y m Helsinki and Uusimaa feces 2013/09 CVB4
7−13 2w f Helsinki and Uusimaa feces 2013/10 CVA16
8−13 13y f Helsinki and Uusimaa feces 2013/10 CVB3
9−13 2y7m f North Savo vesicle 2013/10 CVA6
10−13 1m m North Savo serum 2013/10 PEV-A3
11−13 4d m Helsinki and Uusimaa throat swab 2013/10 CVA16
12−13 1m f Helsinki and Uusimaa feces 2013/11 E25
13−13 1m m Helsinki and Uusimaa feces 2013/11 CVB1
CSF 2013/11 CVB1
14−13 12y m Helsinki and Uusimaa vesicle 2013/11 CVB3
15−13 19y m Helsinki and Uusimaa vesicle 2013/12 CVA6
1−14 7m m Helsinki and Uusimaa vesicle 2014/01 CVA2
2−14 32y m Helsinki and Uusimaa vesicle 2014/02 CVA6
3−14 25y f Helsinki and Uusimaa CSF 2014/05 E4
4−14 14y m Helsinki and Uusimaa feces 2014/05 E4
5−14 12y m Central Finland CSF 2014/06 E4
6−14 24y f Helsinki and Uusimaa CSF 2014/07 E4
7−14 27y f Helsinki and Uusimaa feces 2014/07 E4
8−14 1y m North Savo vesicle 2014/07 CVA6
9−14 15y f Helsinki and Uusimaa CSF 2014/09 E4
10−14 54y f Helsinki and Uusimaa vesicle 2014/09 CVA16
11−14 16y f Helsinki and Uusimaa CSF 2014/09 E4
12−14 14y m Helsinki and Uusimaa CSF 2014/09 E30
13−14 9m m Helsinki and Uusimaa vesicle 2014/09 CVA6
14−14 1y11m f North Karelia serum 2014/10 CVA6
15−14 1m m North Savo serum 2014/09 PEV-A3
16−14 1.5m m Helsinki and Uusimaa feces 2014/10 PEV-A3
17−14 6y m Helsinki and Uusimaa feces 2014/10 CVB4
CSF 2014/10 CVB4
18−14 27y m North Karelia CSF 2014/10 E4
19−14 59y m South Karelia throat swab 2014/10 CVA6
20−14 3m m Central Finland CSF 2014/10 CVA6
21−14 31y f Helsinki and Uusimaa CSF 2014/11 E9
22−14 6m f Helsinki and Uusimaa vesicle 2014/11 CVA6
23−14 39y f Central Finland serum 2014/11 CVA6
24−14 5m m Helsinki and Uusimaa vesicle 2014/11 CVA16
25−14 4y m Helsinki and Uusimaa vesicle 2014/11 CVA6
26−14 6m f Southwest Finland vesicle 2014/12 CVA6
CSF, cerebrospinal fluid; NA, not available; NPA, nasopharyngeal aspirate; m, months; y, years; E, echovirus; CVA, coxsackievirus A; CVB, coxsackievirus B.
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level) to the other clusters, whereas the two strains from Poland (year
2001) showed 17.8–23.9 % divergence at nucleotide level (5.2−13.8 %
at amino acid level) to the other clusters. All the other strains (n=123)
formed a large cluster with high posterior probability support and a
maximum of 22.3 % intra-cluster divergence at nucleotide level (12.2 %
at amino acid level). This large cluster was further divided into several
sub-clusters.
The E4 strains sequenced in this study grouped into several distinct
sub-clusters (Fig. 1). Notably, there was both geographical and tem-
poral variation in the clustering pattern. The ‘epidemic’ strains
(2013–2014) from Germany, Denmark, Sweden, Finland, Norway and
Iceland clustered together. Three strains from Neumunster, Germany
(2012) formed an outgroup in this cluster. These two clusters rooted to
a strain isolated in Hamburg, Germany in the year 2006 (Table 3). All of
these strains clustered with E4 strains detected in Kenya in the year
1999.
The strains from Germany (2003–2009) and Lyon, France
(2008–2015) (Table 3) formed another large cluster together with the
strains previously sequenced in Tunisia [20]. The other strains se-
quenced in this study formed smaller clusters interspersed throughout
the phylogenetic tree, often with no clear geographic pattern. Alto-
gether, this suggests efficient geographical spread of E4 lineages.
4. Discussion
Echovirus 4 (E4) belongs to Enterovirus B species within family
Picornaviridae, and has previously caused outbreaks of viral meningitis
in several countries, including United Kingdom (Scotland), Spain Israel,
Italy, Greece, Australia and Tunisia [21–29]. Long-term surveillance
data suggests that E4 outbreaks are followed by irregular intervals of
low activity [30]. In addition to E4, meningitis cases caused by other
echoviruses have been reported regularly in Europe and Asia [31–36].
Here, we report clusters of E4 strains in Finland, Sweden, Norway,
Denmark, Iceland and Germany, during the years 2013–2014.
Clustering of the ‘epidemic’ strains to E4 strain 06–40 from Hamburg,
Germany in 2006, and E4 strains detected in Kenya in 1999 indicated
common origin. However, due to the relatively high genetic distance
between the Kenyan strains and the strain 06–40 from Germany (esti-
mated tMRCA=1987 [95 % HPD 1974–1997]), the transmission
pathway to Germany cannot be inferred based on the current data. Most
likely, this E4 lineage has circulated silently for a prolonged period.
Notably, none of the strains isolated in Lyon, southern France (years
2008−15, mainly 2012) grouped with the epidemic strains detected in
this study, but instead formed two distinct clusters with strains isolated
mainly in Europe). Thus, the increased E4 circulation in France, on one
side, and in Germany and Northern Europe, on the other side, occurred
almost in parallel (2012–2014), but was caused by distinct E4 lineages
Table 3
E4 infections reported by the collaborating laboratories via E4 query.
Country (median age, years) Age (y/m) Sex (f/m) Region/City/Country Diagnosis/symptoms reported Sample type Sampling time (year/month) Virus
Sweden (22) 17y f Stockholm meningitis CSF 2014/04 E4
20y f Stockholm meningitis CSF 2014/05 E4
23y f Uppsala meningitis feces 2014/06 E4
38y m Stockholm meningitis CSF 2014/08 E4
feces 2014/09 E4
Norway (44) 44y f Kristiansand meningitis/encephalitis feces 2014/06 E4
Iceland (30) 24y NA Iceland meningitis CSF 2013/10 E4
35y NA Iceland meningitis CSF 2014/08 E4
Germany (25) 25y m Homburg/Saar meningitis CSF 2013/NA E4
42y m Homburg/Saar meningitis feces 2013/NA E4
42y m Homburg/Saar meningitis feces 2013/NA E4
29y f Halle (Saale) meningitis CSF 2014/NA E4
7y m Potsdam meningitis feces 2014/NA E4
16y m Münster meningitis feces 2014/NA E4
3y m Oberschleißheim meningitis feces 2014/NA E4
France (21) 1m Na Lyon fever CSF 2008/09 E4
4y Na Lyon unknown CSF 2008/05 E4
11y Na Lyon unknown throat 2008/07 E4
14y Na Lyon unknown NPA 2008/08 E4
24y m Lyon meningitis CSF 2011/07 E4
40y f Lyon meningitis CSF 2011/09 E4
21y f Lyon meningitis CSF 2011/09 E4
24y f Lyon meningitis CSF 2012/07 E4
21y f Lyon meningitis CSF 2012/07 E4
23y m Lyon meningitis CSF 2012/08 E4
9y f Lyon meningitis CSF 2012/09 E4
6y m Lyon meningitis CSF 2012/09 E4
22y m Lyon meningitis CSF 2012/09 E4
31y m Lyon meningitis CSF 2015/10 E4
Germany (11) 8y m Hamburg meningitis feces 2006/NA E4
15y m Stuttgart meningitis unknown 2006/NA E4
10y f Münster meningitis feces 2007/NA E4
4y m Bocholt meningitis feces 2007/NA E4
5y f Münster meningitis CSF 2007/NA E4
7y m Frankfurt unknown feces 2008/NA E4
11y m Frankfurt meningitis feces 2009/NA E4
15y m Würzburg meningitis feces 2011/NA E4
12y m Neumünster meningitis feces 2012/NA E4
14y m Neumünster meningitis CSF 2012/NA E4
15y f Neumünster meningitis feces 2012/NA E4
Russia (11) 11y m Kyrgyzstan acute infection NA 2005/NA E4
3y f Russia meningitis NA 2006/NA E4
17y f Russia meningitis NA 2006/NA E4
F, female; m, male; CSF, cerebrospinal fluid; NA, not available; NPA, nasopharyngeal aspirate; m, months; y, years; E, echovirus.
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and was not epidemiologically related. This observation is concordant
with the hypothesis of herd immunity fluctuations driving multi-year
patterns of EV circulation [37].
The strains isolated in Germany, Denmark, Finland, Sweden,
Norway and Iceland before the year 2012 (with the exception of the
strain 06–40 from Hamburg, year 2006), did not cluster with the
Fig. 1. Phylogenetic tree of VP1 sequences of E4 available in GenBank (NCBI) and acquired via query carried out in this study.
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epidemic E4 strains occurring during the years of 2012–2014. Most
notably, the lineages that were found in Finland in 1999 and 2008 were
not linked to the 2012–2014 E4 incidence surge, and apparently be-
came extinct in Europe. The emergence-expansion-extinction of E4 sub-
clusters was similar to the circulation patterns observed for E30 in
Europe and in Russia [38,39].
In the Finnish patient cohort, the clinical findings of the patients
were available from Helsinki and Uusimaa district. The E4 infected
patients were adolescents or young adults [5 females, 2 males; median
age: 24y [14–31], and showed symptoms for CNS infection. All but one
patient had slightly elevated C-reactive protein levels. The patient with
normal C-reactive protein level was not admitted to hospital, while the
other E4 cases were hospitalized from two to five days. Six out of eight
E4 strains were isolated/detected from CSF (1 patient in Jyväskylä, and
5 in Helsinki and Uusimaa districts), during the study period. Inter-
estingly, two E4 cases occurred in May but rest of the E4 cases were
detected in timeframe of July until November 2014, which is a more
typical time of the year for season of EV infections in Finland. In 2013,
coxsackievirus A infections were less abundant than in 2014 suggesting
a small CVA6 epidemic in Finland as well during that year.
Overall, E4 virus outbreak was detected in several northern
European countries with severe clinical outcome in 2013−14. This
together with the low prevalence of E4 associated disease incidence in
the previous years in several countries suggest that there was an im-
munologically naïve population that was susceptible to severe E4 in-
fections and resulting in the circulation of epidemic strains in Germany,
Finland, Sweden, Denmark, Norway and Iceland.
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